Eventide Asset Management - BRIDGEBIO PHARMA INC ownership

BRIDGEBIO PHARMA INC's ticker is BBIO and the CUSIP is 10806X102. A total of 221 filers reported holding BRIDGEBIO PHARMA INC in Q1 2023. The put-call ratio across all filers is 0.72 and the average weighting 0.4%.

Quarter-by-quarter ownership
Eventide Asset Management ownership history of BRIDGEBIO PHARMA INC
ValueSharesWeighting
Q3 2023$18,905,365
+16.8%
716,927
-23.8%
0.34%
+24.1%
Q2 2023$16,188,227
+3.7%
941,1760.0%0.27%
-4.2%
Q1 2023$15,604,698
-64.1%
941,176
+32.2%
0.29%
-50.9%
Q2 2021$43,416,000
-1.0%
712,1970.0%0.58%
-10.3%
Q1 2021$43,871,000712,1970.65%
Other shareholders
BRIDGEBIO PHARMA INC shareholders Q1 2023
NameSharesValueWeighting ↓
Aisling Capital Management LP 6,068,125$55,099,00039.31%
M28 Capital Management LP 466,200$4,233,0004.74%
Kohlberg Kravis Roberts & Co. L.P. 31,060,971$282,034,0003.75%
Octagon Capital Advisors LP 933,743$8,478,0002.26%
VIKING GLOBAL INVESTORS LP 26,620,991$241,719,0001.11%
HHLR ADVISORS, LTD. 5,362,014$48,687,0001.04%
Cormorant Asset Management, LP 1,469,179$13,340,0001.01%
Knott David M Jr 213,206$1,936,0000.81%
Fernwood Investment Management, LLC 183,900$1,670,0000.72%
HighVista Strategies LLC 105,942$962,0000.58%
View complete list of BRIDGEBIO PHARMA INC shareholders